Why the study?
Does weight-based dosing of doxorubicin improve safety and pharmacokinetic consistency compared to body surface area-based dosing in dogs?
Population
17 dogs (7 small dogs ≤ 10 kg, 10 large dogs > 10 kg)
Comparison
Single dose of doxorubicin at 30 mg/m2 of body… vs Single dose of doxorubicin at 1 mg/kg of body…
Design
Preclinical
Follow-up
14 days
Authors
Loading...
May support weight-based doxorubicin dosing to limit toxicity in small dogs; leaves open confirmation in prospective veterinary trials.
Does weight-based dosing of doxorubicin improve safety and pharmacokinetic consistency compared to body surface area-based dosing in dogs?
Weight-based dosing (1 mg/kg) of doxorubicin in dogs provides more consistent pharmacokinetics and reduces toxicity in small dogs compared to body surface area-based dosing (30 mg/m2).
Arrington et al. (1994) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: